Vaccin împotriva cancerului de piele: Moderna și Merck anunță rezultate încurajatoare

Merck and Moderna announced positive results from phase 3 clinical trials of their mRNA-based skin cancer vaccine, showing significant survival improvements for advanced melanoma patients. This personalized therapy, named 'intismeran autogen', aims to activate the immune system against cancer cells. The study involved over 1,100 participants and is a step towards market authorization. Following the announcement, Moderna's stock surged significantly. The companies plan to present their findings at a medical congress and seek regulatory approval.